Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PHAR
Upturn stock ratingUpturn stock rating

Pharming Group NV (PHAR)

Upturn stock ratingUpturn stock rating
$11.38
Last Close (24-hour delay)
Profit since last BUY-8.81%
upturn advisory
Consider higher Upturn Star rating
BUY since 8 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: PHAR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $30.67

1 Year Target Price $30.67

Analysts Price Target For last 52 week
$30.67 Target price
52w Low $6.73
Current$11.38
52w High $17.08

Analysis of Past Performance

Type Stock
Historic Profit -35.98%
Avg. Invested days 18
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 779.70M USD
Price to earnings Ratio -
1Y Target Price 30.67
Price to earnings Ratio -
1Y Target Price 30.67
Volume (30-day avg) 3
Beta 0.54
52 Weeks Range 6.73 - 17.08
Updated Date 08/15/2025
52 Weeks Range 6.73 - 17.08
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.14

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-31
When -
Estimate -0.0125
Actual 0.06

Profitability

Profit Margin -2.41%
Operating Margin (TTM) 3.27%

Management Effectiveness

Return on Assets (TTM) 2.85%
Return on Equity (TTM) -3.7%

Valuation

Trailing PE -
Forward PE 169.49
Enterprise Value 780696045
Price to Sales(TTM) 2.29
Enterprise Value 780696045
Price to Sales(TTM) 2.29
Enterprise Value to Revenue 2.3
Enterprise Value to EBITDA 26.45
Shares Outstanding 68514800
Shares Floating 670711932
Shares Outstanding 68514800
Shares Floating 670711932
Percent Insiders -
Percent Institutions 0.09

ai summary icon Upturn AI SWOT

Pharming Group NV

stock logo

Company Overview

overview logo History and Background

Pharming Group NV focuses on developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and immune disorders. It was founded in 1988.

business area logo Core Business Areas

  • Recombinant Human C1 Inhibitor (rhC1INH): Development and commercialization of Ruconest, a recombinant human C1 inhibitor for the treatment of acute hereditary angioedema (HAE) attacks.
  • Leniolimab: Development of Leniolimab, a fully human anti-CD40 monoclonal antibody, for the treatment of autoimmune diseases.
  • Research and Development: Ongoing research and development activities focused on expanding its pipeline of innovative therapies for rare diseases.

leadership logo Leadership and Structure

The leadership team consists of a CEO, CFO, CSO, and other key executives. The organizational structure includes departments for research and development, commercial operations, finance, and legal.

Top Products and Market Share

overview logo Key Offerings

  • Ruconest: Ruconest (recombinant human C1 inhibitor) is Pharming's primary product, used to treat acute attacks of hereditary angioedema (HAE). Competitors include Takeda's Takhzyro and BioCryst's Orladeyo. Market Share is difficult to pinpoint but it is estimated to be less than 20%. Revenue is available in the companyu2019s financial statements.
  • Leniolimab: Leniolimab is a fully human anti-CD40 monoclonal antibody in clinical development for various autoimmune indications. Currently it has no revenue.

Market Dynamics

industry overview logo Industry Overview

The rare disease market is characterized by high unmet medical needs, strong pricing power, and regulatory incentives for orphan drug development.

Positioning

Pharming Group NV is positioned as a specialized biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, with Ruconest as its primary revenue driver.

Total Addressable Market (TAM)

The TAM for HAE and related conditions is estimated to be in the billions of dollars globally. Pharming aims to capture a significant share of this market through continued commercialization of Ruconest and development of new therapies.

Upturn SWOT Analysis

Strengths

  • Established product (Ruconest) with demonstrated efficacy
  • Specialized focus on rare diseases
  • Proprietary technology platform
  • Strong intellectual property protection

Weaknesses

  • Reliance on a single primary product (Ruconest)
  • Limited commercial infrastructure compared to larger pharmaceutical companies
  • Risk of competition from new therapies
  • Regulatory hurdles

Opportunities

  • Expansion of Ruconest into new markets
  • Development of new therapies for rare diseases
  • Strategic collaborations and acquisitions
  • Favorable regulatory environment for orphan drugs

Threats

  • Competition from biosimilars or generics
  • Pricing pressures from payers
  • Clinical trial failures
  • Adverse regulatory decisions

Competitors and Market Share

competitor logo Key Competitors

  • TAK
  • BCRX

Competitive Landscape

Pharming Group NV faces competition from larger pharmaceutical companies with more extensive resources and established market positions. Pharming's competitive advantage lies in its specialized focus on rare diseases and its proprietary technology platform.

Growth Trajectory and Initiatives

Historical Growth: Historical growth would be evaluated based on past revenue growth, profitability, and other key performance indicators. This data is subject to change.

Future Projections: Future growth projections would be based on analyst estimates and company guidance, taking into account factors such as market trends, competition, and regulatory developments. This data is subject to change.

Recent Initiatives: Recent initiatives could include new product launches, strategic partnerships, or acquisitions. This data is subject to change.

Summary

Pharming Group NV is a specialized biopharmaceutical company focused on rare diseases. Ruconest drives current revenue, while Leniolimab offers future potential. Pharming faces competition from larger companies but benefits from a focused strategy and proprietary technology. They need to diversify revenue and look out for new competitive drugs being developed.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Market data is subject to change and accuracy cannot be guaranteed.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pharming Group NV

Exchange NASDAQ
Headquaters -
IPO Launch date 2020-12-23
CEO & Executive Director Mr. Fabrice Chouraqui Ph.D., Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 404
Full time employees 404

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.